艾迪注射液联合SOX方案化疗对中晚期胃癌患者生存期及临床受益的影响

发布时间：2018-04-23 23:13

  本文选题：胃癌 + 中晚期　； 参考：《中药材》2017年05期

【摘要】：目的:探讨艾迪注射液联合SOX方案化疗治疗中晚期胃癌的疗效及对患者生存期、临床受益的影响。方法:将94例中晚期胃癌患者随机分为观察组与对照组各47例。对照组行替吉奥[80 mg/(m~2·d)]+奥沙利铂[130 mg/m~2]化疗(SOX方案),观察组在对照组基础上加用艾迪注射液(60~100 m L/天)。观察比较两组近期疗效、中位疾病进展时间(TTP)、中位生存期(MST),比较两组患者治疗前后临床受益、肿瘤标志物水平、免疫功能指标及血管内皮生长因子(VEGF)水平。结果:观察组近期客观总有效率和疾病控制率分别为55.32%、85.11%,显著高于对照组的42.55%、72.34%(P0.05);治疗后观察组的症状积分、肿瘤标志物(CA125、CA199、CA242、CEA)、免疫功能指标(Treg%、Th17%、Th17/Treg比值)及VEGF水平显著低于对照组(P0.05),KPS评分及综合受益率显著高于对照组(P0.05);观察组TTP、MST分别为10.45、27.36个月,显著高于对照组的8.29、20.65个月(P0.05);观察组的骨髓抑制、胃肠道反应及周围神经毒性显著低于对照组(P0.05)。结论:艾迪注射液联合SOX方案化疗治疗中晚期胃癌能改善临床症状、延长生存期并提高近期疗效,其机制可能与增强免疫和抗VEGF有关。
[Abstract]:Objective: to investigate the efficacy of Aidi injection combined with SOX regimen in the treatment of advanced gastric cancer and its effect on survival and clinical benefit. Methods: 94 patients with advanced gastric cancer were randomly divided into observation group (n = 47) and control group (n = 47). The control group was given tigueo [80 mg/(m~2 d] oxaliplatin [130 mg/m~2] chemotherapy with Sox regimen, and the observation group was treated with Aidi injection (60 min / L / day) on the basis of the control group. The clinical benefits, tumor markers, immune function and vascular endothelial growth factor (VEGF) were compared between the two groups before and after treatment. Results: the objective total effective rate and disease control rate in the observation group were 55.32 and 85.11, respectively, which were significantly higher than those in the control group (42.55) and 72.34% (P0.05) respectively, the symptom score of the observation group after treatment was significantly higher than that of the control group (P < 0.05). Tumor marker CA125CA199CA242CEA, the ratio of Tregmy Th17 / Th17 / Treg) and VEGF were significantly lower than those of the control group (P0.05) and the comprehensive benefit rate was significantly higher than that of the control group (P 0.05), the TTPMST of the observation group was 10.45,27.36 months, which was significantly higher than that of the control group (8.29, 20.65 months), and the bone marrow depression of the observation group was significantly higher than that of the control group (P 0.05), and the TTPMST of the observation group was significantly higher than that of the control group (P < 0.01). Gastrointestinal reaction and peripheral neurotoxicity were significantly lower than those of control group (P 0.05). Conclusion: Aidi injection combined with SOX regimen can improve the clinical symptoms, prolong the survival time and improve the short-term curative effect of advanced gastric cancer. The mechanism may be related to enhanced immunity and anti-.
【作者单位】： 南京中医药大学;南京中医药大学附属医院;
【基金】：江苏省中医药科技项目(YB2015017)
【分类号】：R735.2

【相似文献】

中国期刊全文数据库 前10条

1 李桂香,范晓萍;艾迪注射液在肺癌综合治疗中的疗效观察[J];甘肃科技;2003年11期

2 王丽青,张秀平;中药艾迪注射液配合化疗治疗恶性肿瘤30例[J];中国民间疗法;2003年02期

3 朱广媛;李东华;张树范;李笑然;;艾迪注射液的临床研究进展[J];中医药学报;2010年01期

4 胡黎川;杨秀斐;苏银法;白学敏;;96例肿瘤患者应用艾迪注射液的回顾性调查[J];医药导报;2012年03期

5 杨志银;滕川;张丽丽;;化疗联合艾迪注射液治疗中晚期非小细胞肺癌临床分析[J];中国药物经济学;2013年S3期

6 陈家俊,赖义勤,陈云莺;艾迪注射液配合化疗治疗晚期恶性肿瘤31例临床观察[J];中医药通报;2002年03期

7 赵兴;艾迪注射液配合放、化疗治疗恶性肿瘤的临床观察[J];中国中西医结合杂志;2003年09期

8 罗彪,陆启峰,张倬彬;艾迪注射液与放化疗合用治疗恶性肿瘤[J];临床肿瘤学杂志;2003年04期

9 张艳玲,梁后杰;艾迪注射液用于晚期恶性肿瘤的疗效观察[J];肿瘤防治杂志;2003年02期

10 杨卫兵,王家辉,李中文,李宁;艾迪注射液配合化疗对晚期癌症患者生活质量的影响[J];中国中西医结合杂志;2003年11期

中国重要会议论文全文数据库 前10条

1 罗珠林;;必须转变观念——积极开展中晚期胃癌的综合治疗[A];中国中西医结合学会第十八次全国消化系统疾病学术会议暨2006年全国中西医结合消化系统疾病进展学习班论文汇编[C];2006年

2 魏品康;;中晚期胃癌中西药临床联合应用研究[A];中国中西医结合学会第十五次全国消化系统疾病学术研讨会论文汇编[C];2003年

3 曹建民;孔伟东;;中晚期胃癌动脉内介入化疗的临床价值[A];第三届全国肿瘤介入大会暨肿瘤介入进展学术研讨会论文汇编[C];2005年

4 王凤玮;张金泰;薛春利;王新卓;蔡玉梅;尹晓东;薛涛;王立平;;21例中晚期胃癌术后三维适形同步放化疗的近期疗效分析[A];2007第六届全国放射肿瘤学学术年会论文集[C];2007年

5 彭元忠;邓光华;李自瑜;;中晚期胃癌的彩色多普勒超声诊断价值[A];全国医学影像技术学术会议（CMIT-2004）论文汇编[C];2004年

6 刘振玉;付华;杨絮;胡洋;;中晚期胃癌的介入治疗体会[A];第十二届全国临床医学影像学术会议、第四届东北三省放射学术会议论文汇编[C];2002年

7 王敏;安y幭，

本文编号：1794066